Skip to content

Sections
- Health
- Pharma
- Biotech
- Hospitals
- Politics
- In the Lab
- First Opinion
- Gut Check
- The Watchdogs
Topics
Multimedia
Popular
STAT Plus

Job Board
About Us

Newsletters
My Account
- Settings
- Log Out

Newsletters
My Account
- Settings
- Log Out

FDA

Pharmalot

Lapses by EpiPen manufacturer tied to ‘serious’ problems, patient deaths, FDA says

By Ed Silverman

Pharmalot

Pharmalittle: FDA places hold on Celgene and Bristol trials; AstraZeneca-Amgen asthma drug looks strong

By Ed Silverman

advertisement

Biotech

Sarepta’s new DMD drug helps patients produce a crucial protein — but may not quiet critics

By Adam Feuerstein

advertisement

Biotech

Insmed inhaled antibiotic clears rare lung disease in pivotal study

By Adam Feuerstein

Adam's Take

Cellectis off-the-shelf CAR-T therapy grounded following patient’s toxic death

By Adam Feuerstein

Adam's Take

Gilead Sciences boxed in by Novartis’ bargain-bin CAR-T price strategy

By Adam Feuerstein

Adam's Take

A new Parkinson’s drug is a long-acting version of a cheap generic. Should it cost $30,000 a year?

By Adam Feuerstein

advertisement

Pharmalot

Pharmalittle: Roche profits by tweaking an old drug; specialty pharmacy fined for kickbacks

By Ed Silverman

advertisement

Adam's Take

Aerie’s drug manufacturing risk reliever; September biotech events on tap

By Adam Feuerstein

Adam's Take

FDA approval of Aerie Pharma glaucoma drug jeopardized by problems outside its control

By Adam Feuerstein

Adam's Take

The biotech mailbag: Your questions answered on Clovis Oncology, CytRx, Brainstorm Therapeutics, and more

By Adam Feuerstein

Business

Three storylines to watch from Biogen earnings & Dynavax tries again to win hepatitis B vaccine approval

By Adam Feuerstein

Adam's Take

TherapeuticsMD path to drug approval still fuzzy, CytRx CEO on the hot seat

By Adam Feuerstein

Biotech

Novartis CAR-T cancer therapy wins expert support for FDA approval

By Adam Feuerstein and Damian Garde

Biotech

FDA rejects Ocular Therapeutix eye drug, citing manufacturing issues

By Adam Feuerstein

Biotech

Trump’s FDA may be lowering the standards for drug approvals. What’s the fallout?

By Adam Feuerstein

Pharmalot

FDA is reviewing generic applications faster, but what about those carryover fees?

By Ed Silverman

Pharmalot

Pharmalittle: Will index funds join the Mylan revolt? Sanofi plows big bucks into biologics

By Ed Silverman

Pharmalot

Trump plan to have industry pay for all product reviews will likely go nowhere

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: Pfizer gives a cancer drug away in the UK while waiting on coverage decision

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: Novartis is fined $49 million for paying bribes in South Korea

By Ed Silverman

Pharmalot

Lawmaker wants to make it easier for pharma to talk off-label drug use

By Ed Silverman

Pharmalot

How bad is the latest Lilly setback? Here’s what the wags are saying

By Ed Silverman

Pharmalot

Winners and losers: Who had a good week—and who didn’t

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: Gottlieb deftly handles question at confirmation hearing

By Ed Silverman

Pharmalot

Cancer docs oppose ‘right to try’ laws over concerns about unintended harms

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: Failure to renew user fees could mean 3,000 FDA layoffs

By Ed Silverman

Pharmalot

Say what? FDA warns a drug maker over a plant the UK regulator just blessed

By Ed Silverman

Pharmalot

Winners and losers: Who had a good week — and who didn’t

By Ed Silverman

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

Industry

Sign up for our morning rounds newsletter

Reporting from the frontiers of health and medicine

About Us
Contact Us
The STAT Team
Work at STAT
Job Board
Advertise

Privacy
Comment Policy
Terms

© 2017 STAT

X